Tomorrow Bio specializes in human cryopreservation using proprietary cryoprotection techniques to preserve biological tissues at ultra-low temperatures, preventing cellular damage. The company addresses the challenge of indefinite patient storage by providing secure, long-term preservation solutions in Switzerland, ensuring that individuals can potentially be revived when future medical advancements allow.
Funding
$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The long-term storage of deceased individuals presents a challenge, as traditional methods do not prevent biological decay. Current options lack the potential to leverage future medical technologies for possible revival.
Solution
Tomorrow Bio offers human cryopreservation services, utilizing advanced cryoprotection techniques to preserve biological tissues at ultra-low temperatures, effectively halting decomposition. This process aims to maintain the body's cellular structure, offering the potential for future revival should medical advancements allow. The company ensures secure, long-term storage in a purpose-built facility in Switzerland, providing a stable and secure environment for indefinite preservation. Tomorrow Bio employs a specialized procedure for whole-body field cryoprotection, minimizing delays and potential tissue damage.
Target Audience
Individuals interested in the potential for future revival through advanced medical technologies, and who are seeking long-term preservation solutions for themselves or their loved ones.
Features
- State-of-the-art field cryoprotection to prevent delays and tissue damage during the initial preservation process.
- Custom-engineered equipment sourced from Germany, specifically designed for cryopreservation procedures.
- Long-term patient storage in a secure facility located in Switzerland, known for its stability and rule of law.
- Indefinite storage with no time limit, maintained through a unique corporate structure ensuring long-term stability.
- Liquid nitrogen-based cryopreservation at -196 degrees Celsius, ensuring stable temperatures without reliance on electricity.
- Patient care trust (Tomorrow Patient Foundation) that invests funds to cover maintenance costs indefinitely.